Followers | 8 |
Posts | 2087 |
Boards Moderated | 0 |
Alias Born | 07/31/2006 |
Monday, April 27, 2009 9:31:49 PM
Ludlow Capital Group today posted an 18 1/2 minute interview with NanoViricides CEO Eugene Seymour that was conducted by telephone two days ago on the 25th.
http://www.ludlowcapital.com/reports/bio/nnvc.html
The interview is very interesting relative to the current Swine Flu outbreak, and contains some new information about the company's progress toward licensing of it's Flu and HIV drugs.
I have gone through the 18 minute 30 second interview and summarized what I believe to be several important passages, which I present below.
I also was able to "clean up" some of the telephone hum and balance out some of the audio levels, making the interview much easier to understand and more pleasant to listen to. I've uploaded this cleaned up file to some server space:
http://www.MyDocsOnline.com/pub/DaysOnTheBeach/20090427-NNVC-Ludlow.mp3
Dr. Eugene Seymour, CEO NanoViricides, interviewed by Ludlow Capital Group on 4/15/2009
00:00 -- Intros and background of flu viruses. How viruses enter cells and replicate.
07:00 -- Traditional ways to deal with viral illness 1) with vaccines, and 2) with Tamiflu and similar drugs which are typically administered after symptoms develop and attempt to interfere with viral replication.
09:40 NanoViricides presented Flu-Cide data to a major pharma two months ago, demonstrating "excellent results . . . so much better than Tamiflu". The major pharma expressed an interest in moving forward with Flu-Cide.
11:20 -- How NanoViricides' drugs attack viruses, and why they are broad spectrum.
13:15 -- NanoViricides has been spending it's time on HIV and is "in discussions with multiple pharma companies now about our HIV drug . . . we feel that we can achieve what is called a 'functional cure' [for HIV]". CEO Seymour explained his use of the term "functional cure" and described how it is achieved.
15:10 -- Dr. Seymour gave his opinion on the current Swine Flu outbreak, saying "this could be it [could become a pandemic] . . . showing all the signs of 1917 [the beginnings of the Spanish Flu pandemic] . . . it's a perfect storm". CEO Seymour explained what disease characteristics are most conducive to the creation and sustainability of a pandemic.
16:40 -- "We're rushing as fast as we can to build the manufacturing capability to produce a large amount of our drug . . . when you take it it eradicates the virus in the body".
Thank you to Ludlow Capital Group for conducting this interview!
Best to all.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM